Cargando…
Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?
Melanoma is one of the most aggressive forms of skin cancer and is therapeutically challenging, considering its high mutation rate. Following the development of therapies to target BRAF, the most frequently found mutation in melanoma, promising therapeutic responses were observed. While mono- and co...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150731/ https://www.ncbi.nlm.nih.gov/pubmed/34066022 http://dx.doi.org/10.3390/ijms22105115 |